US 12,105,087 B2
Multi-array impedimetric biosensors for the detection of concussion and traumatic brain injuries
Prashant Kumta, Pittsburgh, PA (US); Mitali Patil, Pittsburgh, PA (US); David Okonkwo, Pittsburgh, PA (US); and Robert Kormos, Pittsburgh, PA (US)
Assigned to UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
Appl. No. 16/467,116
Filed by UNIVERSITY OF PITTSBURGH—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION, Pittsburgh, PA (US)
PCT Filed Dec. 11, 2017, PCT No. PCT/US2017/065528
§ 371(c)(1), (2) Date Jun. 6, 2019,
PCT Pub. No. WO2018/107143, PCT Pub. Date Jun. 14, 2018.
Claims priority of provisional application 62/432,119, filed on Dec. 9, 2016.
Prior Publication US 2019/0317089 A1, Oct. 17, 2019
Int. Cl. G01N 33/543 (2006.01); C07K 16/18 (2006.01); G01N 33/68 (2006.01); A61B 5/00 (2006.01); A61B 5/145 (2006.01); G01N 27/00 (2006.01)
CPC G01N 33/54373 (2013.01) [C07K 16/18 (2013.01); G01N 33/5438 (2013.01); G01N 33/6893 (2013.01); A61B 5/145 (2013.01); A61B 5/4064 (2013.01); A61B 2562/0285 (2013.01); G01N 27/00 (2013.01); G01N 2800/2871 (2013.01)] 6 Claims
 
1. A portable, ex-situ system to impedimetrically detect one or more target biomarkers related to brain injury or disease in a bodily fluid sample of a patient, comprising:
a conducting material interface, comprising:
an epoxy resin; and
a multi-array of vertically aligned conducting metal wires selected from the group consisting of platinum wires, gold wires, iridium wires, ruthenium wires, palladium wires, osmium wires, and alloys and combinations thereof, each of the plurality of conducting metal wires having a first end and an opposite second end with the first end cast in the epoxy resin;
a thiol-based compound applied to the second end of the plurality of conducting wires to form a thiol treated surface;
an immobilization agent applied to the thiol treated surface; and
at least one biotinylated antibody and/or aptamer applied to the immobilization agent, selected to bind with the immobilization agent and the one or more target biomarkers related to brain injury or disease;
a signaling agent comprising an electrochemical impedance signal generated by binding of the at least one biotinylated antibody and/or aptamer with the one or more target biomarkers related to brain injury or disease; and
the bodily fluid sample derived from the patient and in contact with the at least one biotinylated antibody and/or aptamer to detect the one or more target biomarkers related to brain injury or disease,
wherein the system is structured such that in its use a change in electrochemical impedance indicates a presence of the one or more target biomarkers related to brain injury or disease in the bodily fluid sample and binding of the at least one biotinylated antibody and/or aptamer with the one or more target biomarkers in the bodily fluid sample, and
wherein the system is structured such that in its use an absence of a change in electrochemical impedance indicates an absence of the one or more target biomarkers related to brain injury or disease in the bodily fluid sample.